nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—CYP3A4—Cytarabine—lymphatic system cancer	0.0916	0.318	CbGbCtD
Salbutamol—CYP3A4—Teniposide—lymphatic system cancer	0.0902	0.313	CbGbCtD
Salbutamol—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0631	0.219	CbGbCtD
Salbutamol—CYP3A4—Vincristine—lymphatic system cancer	0.0434	0.151	CbGbCtD
Salbutamol—Dyspepsia—Fludarabine—lymphatic system cancer	0.00178	0.0025	CcSEcCtD
Salbutamol—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00177	0.00248	CcSEcCtD
Salbutamol—Decreased appetite—Fludarabine—lymphatic system cancer	0.00175	0.00247	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00174	0.00245	CcSEcCtD
Salbutamol—Fatigue—Fludarabine—lymphatic system cancer	0.00174	0.00245	CcSEcCtD
Salbutamol—Inflammation—Methotrexate—lymphatic system cancer	0.00173	0.00243	CcSEcCtD
Salbutamol—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00173	0.00243	CcSEcCtD
Salbutamol—Constipation—Fludarabine—lymphatic system cancer	0.00173	0.00243	CcSEcCtD
Salbutamol—Pain—Fludarabine—lymphatic system cancer	0.00173	0.00243	CcSEcCtD
Salbutamol—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00171	0.00241	CcSEcCtD
Salbutamol—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00171	0.0024	CcSEcCtD
Salbutamol—Urethral disorder—Vincristine—lymphatic system cancer	0.0017	0.00239	CcSEcCtD
Salbutamol—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.0017	0.00239	CcSEcCtD
Salbutamol—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00169	0.00238	CcSEcCtD
Salbutamol—Hypersensitivity—Teniposide—lymphatic system cancer	0.00169	0.00238	CcSEcCtD
Salbutamol—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00169	0.00238	CcSEcCtD
Salbutamol—Flushing—Carmustine—lymphatic system cancer	0.00169	0.00237	CcSEcCtD
Salbutamol—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00168	0.00236	CcSEcCtD
Salbutamol—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00168	0.00236	CcSEcCtD
Salbutamol—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00166	0.00234	CcSEcCtD
Salbutamol—Asthenia—Teniposide—lymphatic system cancer	0.00165	0.00232	CcSEcCtD
Salbutamol—Malaise—Bleomycin—lymphatic system cancer	0.00164	0.0023	CcSEcCtD
Salbutamol—Pruritus—Teniposide—lymphatic system cancer	0.00163	0.00228	CcSEcCtD
Salbutamol—Arrhythmia—Carmustine—lymphatic system cancer	0.00162	0.00228	CcSEcCtD
Salbutamol—Cardiac disorder—Vincristine—lymphatic system cancer	0.00161	0.00226	CcSEcCtD
Salbutamol—Body temperature increased—Fludarabine—lymphatic system cancer	0.0016	0.00224	CcSEcCtD
Salbutamol—Mental disorder—Carmustine—lymphatic system cancer	0.00159	0.00224	CcSEcCtD
Salbutamol—Malnutrition—Carmustine—lymphatic system cancer	0.00158	0.00222	CcSEcCtD
Salbutamol—Cough—Bleomycin—lymphatic system cancer	0.00158	0.00222	CcSEcCtD
Salbutamol—Angiopathy—Vincristine—lymphatic system cancer	0.00157	0.00221	CcSEcCtD
Salbutamol—Diarrhoea—Teniposide—lymphatic system cancer	0.00157	0.00221	CcSEcCtD
Salbutamol—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00156	0.0022	CcSEcCtD
Salbutamol—Chest pain—Bleomycin—lymphatic system cancer	0.00154	0.00217	CcSEcCtD
Salbutamol—Myalgia—Bleomycin—lymphatic system cancer	0.00154	0.00217	CcSEcCtD
Salbutamol—Back pain—Carmustine—lymphatic system cancer	0.00153	0.00215	CcSEcCtD
Salbutamol—Discomfort—Bleomycin—lymphatic system cancer	0.00153	0.00214	CcSEcCtD
Salbutamol—Mental disorder—Vincristine—lymphatic system cancer	0.00152	0.00214	CcSEcCtD
Salbutamol—Chills—Mitoxantrone—lymphatic system cancer	0.00152	0.00213	CcSEcCtD
Salbutamol—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00151	0.00212	CcSEcCtD
Salbutamol—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00149	0.0021	CcSEcCtD
Salbutamol—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00149	0.00209	CcSEcCtD
Salbutamol—Tremor—Carmustine—lymphatic system cancer	0.00148	0.00208	CcSEcCtD
Salbutamol—Oedema—Bleomycin—lymphatic system cancer	0.00148	0.00208	CcSEcCtD
Salbutamol—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00148	0.00208	CcSEcCtD
Salbutamol—Infection—Bleomycin—lymphatic system cancer	0.00147	0.00207	CcSEcCtD
Salbutamol—Back pain—Vincristine—lymphatic system cancer	0.00146	0.00205	CcSEcCtD
Salbutamol—Vomiting—Teniposide—lymphatic system cancer	0.00146	0.00205	CcSEcCtD
Salbutamol—Agitation—Carmustine—lymphatic system cancer	0.00145	0.00204	CcSEcCtD
Salbutamol—Asthenia—Fludarabine—lymphatic system cancer	0.00145	0.00204	CcSEcCtD
Salbutamol—Rash—Teniposide—lymphatic system cancer	0.00145	0.00204	CcSEcCtD
Salbutamol—Dermatitis—Teniposide—lymphatic system cancer	0.00145	0.00203	CcSEcCtD
Salbutamol—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00144	0.00203	CcSEcCtD
Salbutamol—Headache—Teniposide—lymphatic system cancer	0.00144	0.00202	CcSEcCtD
Salbutamol—Pruritus—Fludarabine—lymphatic system cancer	0.00143	0.00201	CcSEcCtD
Salbutamol—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00143	0.00201	CcSEcCtD
Salbutamol—Back pain—Mitoxantrone—lymphatic system cancer	0.00142	0.002	CcSEcCtD
Salbutamol—Anorexia—Bleomycin—lymphatic system cancer	0.00141	0.00198	CcSEcCtD
Salbutamol—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.0014	0.00197	CcSEcCtD
Salbutamol—Agitation—Vincristine—lymphatic system cancer	0.00139	0.00195	CcSEcCtD
Salbutamol—Hypotension—Bleomycin—lymphatic system cancer	0.00138	0.00194	CcSEcCtD
Salbutamol—Diarrhoea—Fludarabine—lymphatic system cancer	0.00138	0.00194	CcSEcCtD
Salbutamol—Hypertension—Carmustine—lymphatic system cancer	0.00137	0.00192	CcSEcCtD
Salbutamol—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00137	0.00192	CcSEcCtD
Salbutamol—Nausea—Teniposide—lymphatic system cancer	0.00136	0.00192	CcSEcCtD
Salbutamol—Vertigo—Vincristine—lymphatic system cancer	0.00136	0.00191	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00135	0.0019	CcSEcCtD
Salbutamol—Chest pain—Carmustine—lymphatic system cancer	0.00135	0.00189	CcSEcCtD
Salbutamol—Myalgia—Carmustine—lymphatic system cancer	0.00135	0.00189	CcSEcCtD
Salbutamol—Anxiety—Carmustine—lymphatic system cancer	0.00134	0.00189	CcSEcCtD
Salbutamol—Paraesthesia—Bleomycin—lymphatic system cancer	0.00133	0.00187	CcSEcCtD
Salbutamol—Malaise—Mitoxantrone—lymphatic system cancer	0.00133	0.00187	CcSEcCtD
Salbutamol—Dyspnoea—Bleomycin—lymphatic system cancer	0.00132	0.00185	CcSEcCtD
Salbutamol—Hypertension—Vincristine—lymphatic system cancer	0.0013	0.00183	CcSEcCtD
Salbutamol—Oedema—Carmustine—lymphatic system cancer	0.00129	0.00182	CcSEcCtD
Salbutamol—Decreased appetite—Bleomycin—lymphatic system cancer	0.00129	0.00181	CcSEcCtD
Salbutamol—Myalgia—Vincristine—lymphatic system cancer	0.00129	0.00181	CcSEcCtD
Salbutamol—Cough—Mitoxantrone—lymphatic system cancer	0.00128	0.0018	CcSEcCtD
Salbutamol—Infection—Carmustine—lymphatic system cancer	0.00128	0.0018	CcSEcCtD
Salbutamol—Vomiting—Fludarabine—lymphatic system cancer	0.00128	0.0018	CcSEcCtD
Salbutamol—Rash—Fludarabine—lymphatic system cancer	0.00127	0.00179	CcSEcCtD
Salbutamol—Dermatitis—Fludarabine—lymphatic system cancer	0.00127	0.00179	CcSEcCtD
Salbutamol—Hypertension—Mitoxantrone—lymphatic system cancer	0.00127	0.00179	CcSEcCtD
Salbutamol—Pain—Bleomycin—lymphatic system cancer	0.00127	0.00178	CcSEcCtD
Salbutamol—Headache—Fludarabine—lymphatic system cancer	0.00126	0.00178	CcSEcCtD
Salbutamol—Tachycardia—Carmustine—lymphatic system cancer	0.00126	0.00177	CcSEcCtD
Salbutamol—Chest pain—Mitoxantrone—lymphatic system cancer	0.00125	0.00176	CcSEcCtD
Salbutamol—Myalgia—Mitoxantrone—lymphatic system cancer	0.00125	0.00176	CcSEcCtD
Salbutamol—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00125	0.00176	CcSEcCtD
Salbutamol—Anxiety—Mitoxantrone—lymphatic system cancer	0.00125	0.00175	CcSEcCtD
Salbutamol—Discomfort—Mitoxantrone—lymphatic system cancer	0.00124	0.00174	CcSEcCtD
Salbutamol—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00123	0.00173	CcSEcCtD
Salbutamol—Oedema—Vincristine—lymphatic system cancer	0.00123	0.00173	CcSEcCtD
Salbutamol—Anorexia—Carmustine—lymphatic system cancer	0.00123	0.00173	CcSEcCtD
Salbutamol—Infection—Vincristine—lymphatic system cancer	0.00123	0.00172	CcSEcCtD
Salbutamol—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00122	0.00171	CcSEcCtD
Salbutamol—Nervous system disorder—Vincristine—lymphatic system cancer	0.00121	0.0017	CcSEcCtD
Salbutamol—Hypotension—Carmustine—lymphatic system cancer	0.00121	0.0017	CcSEcCtD
Salbutamol—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.0012	0.00169	CcSEcCtD
Salbutamol—Oedema—Mitoxantrone—lymphatic system cancer	0.0012	0.00169	CcSEcCtD
Salbutamol—Nausea—Fludarabine—lymphatic system cancer	0.0012	0.00169	CcSEcCtD
Salbutamol—Infection—Mitoxantrone—lymphatic system cancer	0.00119	0.00168	CcSEcCtD
Salbutamol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00119	0.00168	CcSEcCtD
Salbutamol—Shock—Mitoxantrone—lymphatic system cancer	0.00118	0.00166	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00118	0.00165	CcSEcCtD
Salbutamol—Urticaria—Bleomycin—lymphatic system cancer	0.00118	0.00165	CcSEcCtD
Salbutamol—Anorexia—Vincristine—lymphatic system cancer	0.00118	0.00165	CcSEcCtD
Salbutamol—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00117	0.00165	CcSEcCtD
Salbutamol—Body temperature increased—Bleomycin—lymphatic system cancer	0.00117	0.00164	CcSEcCtD
Salbutamol—Insomnia—Carmustine—lymphatic system cancer	0.00117	0.00164	CcSEcCtD
Salbutamol—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00117	0.00164	CcSEcCtD
Salbutamol—Irritability—Methotrexate—lymphatic system cancer	0.00116	0.00163	CcSEcCtD
Salbutamol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00116	0.00163	CcSEcCtD
Salbutamol—Paraesthesia—Carmustine—lymphatic system cancer	0.00116	0.00163	CcSEcCtD
Salbutamol—Mood swings—Methotrexate—lymphatic system cancer	0.00115	0.00162	CcSEcCtD
Salbutamol—Hypotension—Vincristine—lymphatic system cancer	0.00115	0.00162	CcSEcCtD
Salbutamol—Dyspnoea—Carmustine—lymphatic system cancer	0.00115	0.00162	CcSEcCtD
Salbutamol—Somnolence—Carmustine—lymphatic system cancer	0.00115	0.00161	CcSEcCtD
Salbutamol—Anorexia—Mitoxantrone—lymphatic system cancer	0.00114	0.00161	CcSEcCtD
Salbutamol—Ataxia—Methotrexate—lymphatic system cancer	0.00114	0.00161	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00112	0.00158	CcSEcCtD
Salbutamol—Decreased appetite—Carmustine—lymphatic system cancer	0.00112	0.00158	CcSEcCtD
Salbutamol—Hypotension—Mitoxantrone—lymphatic system cancer	0.00112	0.00158	CcSEcCtD
Salbutamol—Insomnia—Vincristine—lymphatic system cancer	0.00112	0.00157	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00112	0.00157	CcSEcCtD
Salbutamol—Paraesthesia—Vincristine—lymphatic system cancer	0.00111	0.00156	CcSEcCtD
Salbutamol—Constipation—Carmustine—lymphatic system cancer	0.0011	0.00155	CcSEcCtD
Salbutamol—Pain—Carmustine—lymphatic system cancer	0.0011	0.00155	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00109	0.00154	CcSEcCtD
Salbutamol—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00109	0.00153	CcSEcCtD
Salbutamol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00108	0.00152	CcSEcCtD
Salbutamol—Decreased appetite—Vincristine—lymphatic system cancer	0.00107	0.00151	CcSEcCtD
Salbutamol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00107	0.00151	CcSEcCtD
Salbutamol—Somnolence—Mitoxantrone—lymphatic system cancer	0.00107	0.0015	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00106	0.0015	CcSEcCtD
Salbutamol—Feeling abnormal—Carmustine—lymphatic system cancer	0.00106	0.0015	CcSEcCtD
Salbutamol—Fatigue—Vincristine—lymphatic system cancer	0.00106	0.00149	CcSEcCtD
Salbutamol—Asthenia—Bleomycin—lymphatic system cancer	0.00106	0.00149	CcSEcCtD
Salbutamol—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00106	0.00149	CcSEcCtD
Salbutamol—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00106	0.00148	CcSEcCtD
Salbutamol—Pain—Vincristine—lymphatic system cancer	0.00105	0.00148	CcSEcCtD
Salbutamol—Constipation—Vincristine—lymphatic system cancer	0.00105	0.00148	CcSEcCtD
Salbutamol—Asthma—Methotrexate—lymphatic system cancer	0.00105	0.00148	CcSEcCtD
Salbutamol—Pruritus—Bleomycin—lymphatic system cancer	0.00105	0.00147	CcSEcCtD
Salbutamol—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00104	0.00147	CcSEcCtD
Salbutamol—Fatigue—Mitoxantrone—lymphatic system cancer	0.00104	0.00146	CcSEcCtD
Salbutamol—Pain—Mitoxantrone—lymphatic system cancer	0.00103	0.00144	CcSEcCtD
Salbutamol—Constipation—Mitoxantrone—lymphatic system cancer	0.00103	0.00144	CcSEcCtD
Salbutamol—Abdominal pain—Carmustine—lymphatic system cancer	0.00102	0.00144	CcSEcCtD
Salbutamol—Body temperature increased—Carmustine—lymphatic system cancer	0.00102	0.00144	CcSEcCtD
Salbutamol—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00101	0.00142	CcSEcCtD
Salbutamol—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00099	0.00139	CcSEcCtD
Salbutamol—Dysuria—Methotrexate—lymphatic system cancer	0.000984	0.00138	CcSEcCtD
Salbutamol—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000982	0.00138	CcSEcCtD
Salbutamol—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000978	0.00137	CcSEcCtD
Salbutamol—Abdominal pain—Vincristine—lymphatic system cancer	0.000975	0.00137	CcSEcCtD
Salbutamol—Body temperature increased—Vincristine—lymphatic system cancer	0.000975	0.00137	CcSEcCtD
Salbutamol—Urticaria—Mitoxantrone—lymphatic system cancer	0.000954	0.00134	CcSEcCtD
Salbutamol—Hypersensitivity—Carmustine—lymphatic system cancer	0.000952	0.00134	CcSEcCtD
Salbutamol—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000949	0.00133	CcSEcCtD
Salbutamol—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000949	0.00133	CcSEcCtD
Salbutamol—Vomiting—Bleomycin—lymphatic system cancer	0.000941	0.00132	CcSEcCtD
Salbutamol—Drowsiness—Methotrexate—lymphatic system cancer	0.000938	0.00132	CcSEcCtD
Salbutamol—Rash—Bleomycin—lymphatic system cancer	0.000933	0.00131	CcSEcCtD
Salbutamol—Dermatitis—Bleomycin—lymphatic system cancer	0.000932	0.00131	CcSEcCtD
Salbutamol—Asthenia—Carmustine—lymphatic system cancer	0.000927	0.0013	CcSEcCtD
Salbutamol—Stomatitis—Methotrexate—lymphatic system cancer	0.000915	0.00129	CcSEcCtD
Salbutamol—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000912	0.00128	CcSEcCtD
Salbutamol—Hypersensitivity—Vincristine—lymphatic system cancer	0.000909	0.00128	CcSEcCtD
Salbutamol—Sweating—Methotrexate—lymphatic system cancer	0.0009	0.00126	CcSEcCtD
Salbutamol—Haematuria—Methotrexate—lymphatic system cancer	0.000895	0.00126	CcSEcCtD
Salbutamol—Epistaxis—Methotrexate—lymphatic system cancer	0.000885	0.00124	CcSEcCtD
Salbutamol—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000885	0.00124	CcSEcCtD
Salbutamol—Asthenia—Vincristine—lymphatic system cancer	0.000885	0.00124	CcSEcCtD
Salbutamol—Diarrhoea—Carmustine—lymphatic system cancer	0.000884	0.00124	CcSEcCtD
Salbutamol—Nausea—Bleomycin—lymphatic system cancer	0.000879	0.00124	CcSEcCtD
Salbutamol—Asthenia—Mitoxantrone—lymphatic system cancer	0.000862	0.00121	CcSEcCtD
Salbutamol—Dizziness—Carmustine—lymphatic system cancer	0.000854	0.0012	CcSEcCtD
Salbutamol—Haemoglobin—Methotrexate—lymphatic system cancer	0.000847	0.00119	CcSEcCtD
Salbutamol—Diarrhoea—Vincristine—lymphatic system cancer	0.000844	0.00119	CcSEcCtD
Salbutamol—Haemorrhage—Methotrexate—lymphatic system cancer	0.000842	0.00118	CcSEcCtD
Salbutamol—Pharyngitis—Methotrexate—lymphatic system cancer	0.000836	0.00117	CcSEcCtD
Salbutamol—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000832	0.00117	CcSEcCtD
Salbutamol—Urethral disorder—Methotrexate—lymphatic system cancer	0.000826	0.00116	CcSEcCtD
Salbutamol—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000822	0.00116	CcSEcCtD
Salbutamol—Vomiting—Carmustine—lymphatic system cancer	0.000821	0.00115	CcSEcCtD
Salbutamol—Dizziness—Vincristine—lymphatic system cancer	0.000816	0.00115	CcSEcCtD
Salbutamol—Rash—Carmustine—lymphatic system cancer	0.000815	0.00114	CcSEcCtD
Salbutamol—Dermatitis—Carmustine—lymphatic system cancer	0.000814	0.00114	CcSEcCtD
Salbutamol—Headache—Carmustine—lymphatic system cancer	0.000809	0.00114	CcSEcCtD
Salbutamol—Tinnitus—Methotrexate—lymphatic system cancer	0.000785	0.0011	CcSEcCtD
Salbutamol—Vomiting—Vincristine—lymphatic system cancer	0.000784	0.0011	CcSEcCtD
Salbutamol—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000782	0.0011	CcSEcCtD
Salbutamol—Rash—Vincristine—lymphatic system cancer	0.000778	0.00109	CcSEcCtD
Salbutamol—Dermatitis—Vincristine—lymphatic system cancer	0.000777	0.00109	CcSEcCtD
Salbutamol—Headache—Vincristine—lymphatic system cancer	0.000773	0.00109	CcSEcCtD
Salbutamol—Nausea—Carmustine—lymphatic system cancer	0.000767	0.00108	CcSEcCtD
Salbutamol—Angiopathy—Methotrexate—lymphatic system cancer	0.000764	0.00107	CcSEcCtD
Salbutamol—Vomiting—Mitoxantrone—lymphatic system cancer	0.000764	0.00107	CcSEcCtD
Salbutamol—Immune system disorder—Methotrexate—lymphatic system cancer	0.000761	0.00107	CcSEcCtD
Salbutamol—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000759	0.00107	CcSEcCtD
Salbutamol—Rash—Mitoxantrone—lymphatic system cancer	0.000757	0.00106	CcSEcCtD
Salbutamol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000757	0.00106	CcSEcCtD
Salbutamol—Chills—Methotrexate—lymphatic system cancer	0.000756	0.00106	CcSEcCtD
Salbutamol—Headache—Mitoxantrone—lymphatic system cancer	0.000752	0.00106	CcSEcCtD
Salbutamol—Mental disorder—Methotrexate—lymphatic system cancer	0.000738	0.00104	CcSEcCtD
Salbutamol—Malnutrition—Methotrexate—lymphatic system cancer	0.000733	0.00103	CcSEcCtD
Salbutamol—Nausea—Vincristine—lymphatic system cancer	0.000733	0.00103	CcSEcCtD
Salbutamol—Dysgeusia—Methotrexate—lymphatic system cancer	0.000718	0.00101	CcSEcCtD
Salbutamol—Nausea—Mitoxantrone—lymphatic system cancer	0.000713	0.001	CcSEcCtD
Salbutamol—Back pain—Methotrexate—lymphatic system cancer	0.000709	0.000997	CcSEcCtD
Salbutamol—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00068	0.000956	CcSEcCtD
Salbutamol—Malaise—Methotrexate—lymphatic system cancer	0.000661	0.000929	CcSEcCtD
Salbutamol—Vertigo—Methotrexate—lymphatic system cancer	0.000659	0.000926	CcSEcCtD
Salbutamol—Cough—Methotrexate—lymphatic system cancer	0.00064	0.000899	CcSEcCtD
Salbutamol—Arthralgia—Methotrexate—lymphatic system cancer	0.000624	0.000877	CcSEcCtD
Salbutamol—Myalgia—Methotrexate—lymphatic system cancer	0.000624	0.000877	CcSEcCtD
Salbutamol—Chest pain—Methotrexate—lymphatic system cancer	0.000624	0.000877	CcSEcCtD
Salbutamol—Discomfort—Methotrexate—lymphatic system cancer	0.000617	0.000867	CcSEcCtD
Salbutamol—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000598	0.000841	CcSEcCtD
Salbutamol—Infection—Methotrexate—lymphatic system cancer	0.000595	0.000836	CcSEcCtD
Salbutamol—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000587	0.000825	CcSEcCtD
Salbutamol—Skin disorder—Methotrexate—lymphatic system cancer	0.000581	0.000817	CcSEcCtD
Salbutamol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000579	0.000813	CcSEcCtD
Salbutamol—Anorexia—Methotrexate—lymphatic system cancer	0.00057	0.000802	CcSEcCtD
Salbutamol—Hypotension—Methotrexate—lymphatic system cancer	0.000559	0.000786	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000545	0.000766	CcSEcCtD
Salbutamol—Insomnia—Methotrexate—lymphatic system cancer	0.000541	0.000761	CcSEcCtD
Salbutamol—Paraesthesia—Methotrexate—lymphatic system cancer	0.000537	0.000755	CcSEcCtD
Salbutamol—Dyspnoea—Methotrexate—lymphatic system cancer	0.000534	0.00075	CcSEcCtD
Salbutamol—Somnolence—Methotrexate—lymphatic system cancer	0.000532	0.000748	CcSEcCtD
Salbutamol—Dyspepsia—Methotrexate—lymphatic system cancer	0.000527	0.00074	CcSEcCtD
Salbutamol—Decreased appetite—Methotrexate—lymphatic system cancer	0.00052	0.000731	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000517	0.000726	CcSEcCtD
Salbutamol—Fatigue—Methotrexate—lymphatic system cancer	0.000516	0.000725	CcSEcCtD
Salbutamol—Pain—Methotrexate—lymphatic system cancer	0.000512	0.000719	CcSEcCtD
Salbutamol—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000493	0.000693	CcSEcCtD
Salbutamol—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000489	0.000688	CcSEcCtD
Salbutamol—Urticaria—Methotrexate—lymphatic system cancer	0.000475	0.000668	CcSEcCtD
Salbutamol—Abdominal pain—Methotrexate—lymphatic system cancer	0.000473	0.000665	CcSEcCtD
Salbutamol—Body temperature increased—Methotrexate—lymphatic system cancer	0.000473	0.000665	CcSEcCtD
Salbutamol—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000441	0.00062	CcSEcCtD
Salbutamol—Asthenia—Methotrexate—lymphatic system cancer	0.000429	0.000603	CcSEcCtD
Salbutamol—Pruritus—Methotrexate—lymphatic system cancer	0.000423	0.000595	CcSEcCtD
Salbutamol—Diarrhoea—Methotrexate—lymphatic system cancer	0.000409	0.000575	CcSEcCtD
Salbutamol—Dizziness—Methotrexate—lymphatic system cancer	0.000396	0.000556	CcSEcCtD
Salbutamol—Vomiting—Methotrexate—lymphatic system cancer	0.00038	0.000535	CcSEcCtD
Salbutamol—Rash—Methotrexate—lymphatic system cancer	0.000377	0.00053	CcSEcCtD
Salbutamol—Dermatitis—Methotrexate—lymphatic system cancer	0.000377	0.00053	CcSEcCtD
Salbutamol—Headache—Methotrexate—lymphatic system cancer	0.000375	0.000527	CcSEcCtD
Salbutamol—Nausea—Methotrexate—lymphatic system cancer	0.000355	0.0005	CcSEcCtD
